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DRUG COMPOSITION CYTOTOXIC FOR
PANCREATIC CANCER CELLS

disease progression, but also influence the drug responsiveness. Within the context of the concurrent activation of
EGFR, Src and Stat3 in pancreatic cancer, the potential for
cooperation between EGFR and Src kinases to induce aberrant Stat3 activation and to cooperate in support of the cancer
phenotype is a reasonable model to propose. Knowledge of
this functional relationship and the collective roles of the
proteins in supporting pancreatic cancer can facilitate the
design of effective, multiple-targeted therapy for disease. We
provide evidence that EGFR and Src promote constitutive
Stat3 activation, with a compensatory Stat3 activation mechanism from Jaks, and together support the pancreatic cancer
phenotype. Importantly, our study identifies that the concurrent inhibition of aberrant Stat3 and EGFR or Src is more
effective in inducing antitumor cell response and pancreatic
tumor regression in xenografts.

CROSS-REFERENCE TO RELATED
APPLICATIONS
This application is a national phase application oflnternational Application No. PCT/US2009/06607 9, which was filed
on 30 Nov. 2009, which claims priority to U.S. provisional
application Ser. No. 61/118,792, which was filed on 1 Dec.
2008, and to U.S. provisional application Ser. No. 61/249,
307, which was filed on 7 Oct. 2009, each application of
which is incorporated herein by reference in its entirety.
STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH OR DEVELOPMENT
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The invention was made with government support under
ROI CAI 06439 awarded by the National Institutes of Health.
20
The government has certain rights in the invention.
FIELD OF THE INVENTION
The present invention relates to the field of drug development and, more particularly, to a drug composition cytotoxic
for pancreatic cancer cells.
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BACKGROUND OF THE INVENTION
Pancreatic cancer is a lethal disease with a poor prognosis
and a mortality rate nearly the same as the rate of incidence.
Moreover, the disease remains poorly understood. Multiple
signal transduction proteins are activated during pancreatic
ductal cell carcinogenesis, some may be secondary events,
while many others might have critical roles and collectively
contribute to the maintenance and the progression of the
disease and its responsiveness to therapy. One of the major
molecular abnormalities is the overexpression and/or activation of the EGFR protein, which has an incidence of30-50%
of pancreatic cancer cases (1). Evidence indicates that the
hyperactive EGF /EGFR duo is important in the disease maintenance and progression (2). Similarly, the overexpression of
the c-Src tyrosine kinase occurs in a large percentage of
pancreatic adenocarcinoma and is observed to augment
EGFR activities during tumorigenesis (3, 4). The over-activity of Src family kinases leads to deregulation of tumor cell
growth and survival, disruption of cell-to-cell contacts, and
the promotion of migration and invasiveness, and the induction of tumor angiogenesis (4, 5).
Another molecular abnormality is the aberrant activation
ofStat3, a member of the Signal Transducer and Activator of
Transcription (STAT) family of cytoplasmic transcription
factors, which has also been detected in pancreatic tumors
and tumor cell lines and been implicated in the disease (6-9).
Stat3, as are the other STATs, requires extrinsic tyrosine
phosphorylation to become activated and this is induced by
growth factor receptors and cytoplasmic tyrosine kinases,
such as Src and Janus kinase (Jaks) families (10). In contrast
to normal STAT signaling that is transient in accordance with
the requirements for normal biological processes, tumor cells
harbor aberrant Stat3 activation. Studies show that aberrant
Stat3 dysregulates cell growth and survival, promotes tumor
angiogenesis, cell migration and invasion, and induces tumor
immune tolerance (11-13).
De-regulated signal transduction provides the framework
for functional cooperativity and signaling cross-talk that
would not only support the malignant phenotype and the
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SUMMARY OF THE INVENTION
With the foregoing in mind, the present invention advantageously provides a cytotoxic composition containing a drug
combination targeting two or more functional elements in
pancreatic cancer cells, the functional elements comprising
EGFR or Src and Stat3 or Jaks. A preferred embodiment of
the cytotoxic composition is one wherein the drug combination contained therein is selected from ZD and S3I-201, Das
and S31-201, ZD andAG490, Das andAG490, and combinations thereof. Furthermore, the preferred cytotoxic composition is that wherein the drug combination inhibits said functional elements at substantially the same time. The preferred
composition of the present invention may also comprise a
nucleoside analog inhibitory for DNA replication, for
example, Gemcitabine.
The invention herein disclosed also includes a method of
cytotoxically affecting (which could result in killing) pancreatic cancer cells, the method comprising contacting the cells
with a drug combination which inhibits two or more cellular
functional elements, the functional elements including EGFR
or Src and Stat3 or Jaks. The method of the invention also
includes an embodiment wherein the drug combination is
selected from ZD and S31-201, Das and S31-201, ZD and
AG490, Das and AG490, and combinations thereof. A preferred method of the invention also includes contacting the
cells with a drug combination further comprising a nucleoside analog inhibitory for DNA replication, the nucleoside
analog preferably being Gemcitabine.
The invention additionally includes a method of making a
therapeutic medication cytotoxic for pancreatic cancer cells,
the method comprising preparing a pharmaceutically acceptable composition containing a drug combination selected
from ZD and S31-201, Das and S31-201, ZD andAG490, Das
and AG490, and combinations thereof. The method of making the medication preferably also includes an embodiment
wherein the drug combination further comprises a nucleoside
analog inhibitory for DNA replication, for example, Gemcitabine.
BRIEF DESCRIPTION OF THE DRAWINGS
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Some of the features, advantages, and benefits of the
present invention having been stated, others will become
apparent as the description proceeds when taken in conjunction with the accompanying drawings in which:
FIG. 1 shows EMSA and immunoblotting analyses of
Stat3, Src and EGFR activities for effects of inhibitors. (A)
EMSA analysis of STAT DNA-binding activity using (i)
high-affinity sis-inducible element (hSIE) probe that binds
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Stat3 and Statl or (ii) mammary gland factor element (MGFe)
probe that binds Statl or Stat5; and (Band C) Immunoblotting analysis ofwhole-cell lysates from cells (B) (i) untreated
or (ii) treated with ZD 1839 (ZD), or Dasatinib (Das), or
transfected with or without (iii) Src siRNA, (iv) EGFR
siRNA, or scrambled siRNA control (con) and probing for
pY416c-Src (pY416Src), Src, pY845EGFR, and EGFR; and
(C) untreated or treated with ZD or Das and probing for (i)
pYI 068EGFR, (ii) pYI 086EGFR and (iii) pYI I 73EGFR,
and EGFR. Positions of STAT:DNA complexes in gel are
shown; *Supershifts were performed with antibodies specifically recognizing either Statl (a-Statl), Stat3 (a-Stat3), or
Stat5 (a-Stat5a or a-Stat5b); asterisk indicates position of
supershifted complexes. Data are consistent with those
obtained from 4 independent experiments.
FIG. 2 depicts EMSA and immunoblotting analyses for
effects of inhibitors on Stat3. (A and B) EMSA analysis of
Stat3 DNA-binding activity in (A) Pane-I or (B) Colo-357
cells treated or untreated with the pan ErbB inhibitor,
PD169540 (PD169), ZD 1839 (ZD), Dasatinib (Das), the Jak
inhibitor, AG490, the ErbB2-selective inhibitor, AG879, or
inhibitor combinations for the indicated times, or (C) immunoblotting analysis of whole-cell lysates from Pane-I cells
transfected with EGFR siRNA, Src siRNA, or scrambled
siRNA (control) and probing for pStat3 or Stat3. *Supershift
analysis. Data are consistent with those obtained from 3 independent experiments.
FIG. 3 presents data of cell viability studies for effects of
inhibitors. (A and B) Trypan blue exclusion/phase-contrast
microscopy for viable Pane-I or Colo-357 cells following
treatment for 0-96-h inhibitor with I µM ZD, I 00 nM Das, 50
µM S3 l-201, Jak inhibitor, AG490, or combinations; (C and
D) CyQuant cell proliferation assay for viability of Pane-I (C,
left panel, and D(i)) or Colo-357 cells (C, right panel and
D(ii)) for effects of 48-h treatments with the designated concentrations of ZD, Das, S3 l-201, Gemcitabine (Gem) alone
and in combinations. Values, mean and S.D., n=4 experiments
each in triplicates. p values, *-<0.05, **-<0.01, and ***<0.001.
FIG. 4 shows colony survival and apoptosis studies for
effects of inhibitors. (A) Number of colonies emerging from
cells in culture (500 per 6 cm dish) untreated or treated once
with ZD1839 (ZD), Dasatinib (Das), S3I-201 (S3I), or combinations and allowed to culture; or (B) Annexin V binding/
Flow Cytometry analysis of normal HPDEC, Pane-I or Colo357 cells treated or untreated with inhibitors or combinations.
Values, mean and S.D., n=4 experiments each in triplicates. p
values, *-<0.05, **-<0.01, and ***-<0.001.
FIG. 5 presents the concurrent inhibition of Stat3 and
EGFR or Src inhibits migration and invasion and suppresses
c-Myc expression. (A) Effects of ZDl839 (ZD), Dasatinib
(Das), and/or S3I-201 (S3I) on migration and invasion; (B)
Immunoblotting analysis ofwhole-cell lysates for c-Myc and
b-Actin expression in Pane-I cells. Values, mean and S.D.,
n=3-4 experiments each in triplicates. p values, *-<0.05,
**-<0.01, and ***-<0.001.
FIG. 6 is a line graph showing progression of tumor volume
under the different therapies; concurrent inhibition of Stat3
and EGFR or Src induces human pancreatic tumor growth
inhibition in xenografts.

Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which this invention
pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or
testing of the present invention, suitable methods and materials are described below. Any publications, patent applications, patents, and other references mentioned herein are
incorporated by reference in their entirety. In case of conflict,
the present specification, including any definitions, will control. In addition, the materials, methods and examples given
are illustrative in nature only and not intended to be limiting.
Accordingly, this invention may be embodied in many different forms and should not be construed as limited to the illustrated embodiments set forth herein. Rather, these illustrated
embodiments are provided so that this disclosure will be
thorough and complete, and will fully convey the scope of the
invention to those skilled in the art. Other features and advantages of the invention will be apparent from the following
detailed description, and from the claims.
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Materials and Methods
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Nuclear Extract Preparation and Gel Shift Assays.
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Nuclear extract preparation and DNA-binding with electrophoretic mobility shift assay (EMSA) were carried out, as
previously reported (14, 15). The 32 P-labeled oligonucleotide
probes used were hSIE (high affinity sis-inducible element
from the c-fos gene, m67 variant), 5'-AGCTTCATTTCCCGTAAATCCCTA; (SEQ ID NO: I) that binds Statl and Stat3
(Wagner et al., 1990) and the MGFe (mammary gland factor
element from the bovine ~-casein gene promoter, 5'-AGATTTCTAGGAATTCAA; (SEQ ID N0:2) that binds Statl
and Stat5 (Gouilleux et al., 1995; Seidel et al., 1995).
SDS-PAGE/Westem Blot Analysis.
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DETAILED DESCRIPTION OF PREFERRED
EMBODIMENTS
The present invention will now be described more fully
hereinafter with reference to the accompanying drawings, in
which preferred embodiments of the invention are shown.

Cells and Reagents.
v-Src-transformed mouse fibroblasts (NIH3T3/v-Src),
human pancreatic cancer (Pane-I) and leukemic (K562) lines
have been described (14-16). The human pancreatic cancer
lines, Colo-357 and Mia-PaCa-2 were kind gifts from Drs.
Lancaster and Mokenge (Moffitt Cancer Center). The immortalized human pancreatic duct epithelial cell (HPDEC) line
was obtained from Dr. Tsao, OCI, UHN-PMH, Toronto) (17).
Except for HPDEC grown in Keratinocyte-SFM media
supplemented with 0.2 ng EGF, 30 µg/mL bovine pituitary
extract and containing antimycol, and K562 line in RPMI
1640 containing I 0% heat-inactivated FBS and 100 units/ml
penicillin-streptomycin, all other cell lines were grown in
Dulbecco's modified Eagle's medium (DMEM) containing
5% iron-supplemented bovine calf serum and I 00 units/ml
penicillin-streptomycin. Recombinant human EGF (hEGF) is
from Creative Biolabs, Port Jefferson Station, N.Y.); Gemcitabine is from Ely Lilly (Indianapolis, Ind.).

Western blotting analysis was performed as previously
described (15, 18). Primary antibodies used were anti-Stat3
(C20) (Santa Cruz, Santa Cruz, Calif.), anti-pY845EGFR
(Upstate Biotech, Millipore, Billerica, Mass.), and antibodies
against pY705Stat3, Stat3, pYI 068EGFR, pYI 086EGFR,
pY1173EGFR, EGFR, pY416Src, Src, c-Myc, and ~-Actin
from Cell Signaling (Danvers, Mass.).
Inhibitors
The inhibitors used herein are known to the art.
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ZD or ZDl839 (Iressa™) is also referred to as Gefitinib
(CAS No. 184475-32-2). ZDl839 has the molecular formula
C 22 H 24ClFN4 0 3 . ZD has the formula:
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See References 24 and 25.
S3I-201 or S3I is also referred to as NSC 74859 (Cas No.
501919-59-1). S3I has the molecular formula C 16H 15 N0 7 S.
S3I has the formula:
0

0

(Y~TI)Y~
HOYY
~.
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20
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See Reference 30.
Das or Dasatinib (Sprycel™) is also referred to as BMS354825 (CAS No. 302962-49-8). Das has the molecular formula C 22 H 26 ClN7 0 2 S. Das has the formula:
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See Reference 23, 29, and 35.
AG490 is also referred to as TyrphostinAG490 (CAS No.
133550-30-8). AG490 has the molecular formula
C 17H 14N 2 0 3 . AG490 has the formula:

45
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See Reference 14.
Small-Interfering RNA (siRNA) Transfection.
siRNA sequences for EGFR and Src were ordered from
Dharmacon RNAi Technologies, Thermo Scientific (Lafayette, Colo.). Sequences used are: EGFR sense strand,
5'-GAAGGAAACUGAAUUCAAAUU-3', SEQ ID N0:3;
EGFR antisense strand, 5'-UUUGAAUUCAGUUUCCUUCUU-3, SEQ ID N0:4'; control siRNA sense strand,
5'-AGUAAUACAACGGUAAAGAUU-3', SEQ ID N0:5;
and control siRNA antisense strand, 5'-UCUUUACCGUUGUAUUACUUU-3', SEQ ID N0:6. The c-Src SMARTpool
siRNA reagent (NM-005417, Catalog #M-003175-01-05)

60

65

was used for Src. Transfection into cells was performed using
20 nM of EGFR siRNA or 25 nM of Src siRNA and 8 µl
Lipofectamine RNAiMAX (Invitrogen Corporation, Carlsbad, Calif.) in OPTI-MEM culture medium (GIBCO, Invitrogen).
Cell Proliferation Viability Assay andAnnexin V Binding and
Flow Cytometry.
Proliferating cells in 6-well or 96-well plates were treated
once with 0.1-1 mM ZD 1839 (Iressa) (reference 25), I 00 nM
Dasatinib (references 23 and 35), 50-100 µM S3 l-201, I µM
Gemcitabine (reference 43 ), or combinations of inhibitors for
up to 96 h. Viable cells were counted by trypan blue exclusion/phase contrast microscopy or assessed by CyQuant cell
viability assay, according to manufacturer's (Invitrogen)
instructions, or cells were processed for Annexin V binding
(BD Biosciences) with flow cytometry for apoptosis. S31201 is fully described in reference 30 (see below).
Colony Survival Assay.
Single-cell suspension of Pane-I and Colo-357 cells were
seeded in 6-cm dishes (500 cells per well) and assayed as
previously reported (19), treated the next day with inhibitors
for 48 h, and allowed to grow until large colonies were visible.
Colonies were stained with crystal violet for 4 hand counted
under phase-contrast microscope.
Cell Migration and Matrigel Invasion Assays.
Cell migration and invasion experiments were carried out and
quantified as previously described (20), using Bio-Coat
migration chambers (Becton Dickinson, Franklin, N.J.) of
24-well companion plates with cell culture inserts containing
8 µm pore size filters, according to the manufacturer's protocol.
Statistical Analysis.
Statistical analysis was performed on mean values using
Prism GraphPad Software, Inc. (La Jolla, Calif.). The significance of differences between groups was determined by
paired t-test at p <0.05*, <0.01 **,and <0.001 ***.
Results
Aberrant EGFR, Src and Stat3 in Pancreatic Cancer Lines.
Consistent with published reports (6, 7), Stat3 activity, per
DNA-binding with EMSA analysis in nuclear extract preparations is constitutive in Pane-I and Colo-357, low in MiaPaca-2, and undetectable in the normal human pancreatic
duct epithelial cells (HPDEC), compared to aberrant levels in
NIH3T3/v-Src (15) (FIG. lA(i)). Per supershift analysis, the
DNA-protein complex contains Stat3 (FIG. lA(i), lane 3). By
contrasts, Stat5 activity is undetectable in pancreatic cancer
cells (FIG. lA(ii)), compared to aberrant levels in the K562
leukemic cells (16).
EGFR and c-Src are aberrant in many human cancers (2, 4).
Immunoblotting analysis showed a moderate pY416c-Src
level in Mia-Paca-2, but enhanced levels in Pane-I and Colo357 cells similar to levels in NIH3T3/v-Src, compared to low
levels in HPDEC (FIG. lB(i), upper panel). The elevated
pY 4 I 6Src levels parallel enhanced levels of the Src-sensitive
pY845EGFR motif (21) in Pane-I and Colo-357 cells, compared to low levels of same in HPDEC (FIG. lB(i), lower
panel). Total Src or EGFR protein remained unchanged.
Immunoblotting analysis further showed elevated levels of
the EGFR autophosphorylation motifs (22), pYI068EGFR
(FIG. lC(i), lanes 2 and 7), pYI086EGFR (FIG. lC(ii), lanes
2 and 7) and pYl I 73EGFR (FIG. lC(iii), lanes 2 and 7) in
Pane-I and Colo-357, compared to basal levels of same in
HPDEC (FIG. lC(i)-(iii), lane I).
Functional Integration ofEGFR and Src in Pancreatic Cancer
Cells.
We next examined the functional relationship between the
activated EGFR and Src. Immunoblotting analysis showed

US 8,685,941 B2

7

8

treatment of cells with Dasatinib (Das) inhibited Src activity
same in response to the stimulation of normal HPDEC
(Supplemental FIG. Sl, lane 2), except for pYI068EGFR
(pY4I6Src) (23) and induced an early (I h) and a sustained
(24 h) decrease in p Y845EGFR levels (FIG. lB(ii)). By conlevels in Pane-I (FIG. Sl(ii), upper right panel). In control
trast, no detectable changes in pY4I6Src and pY845EGFR
studies, immunoblotting analysis showed elevated pErkI/
levels were induced by treatment with the pan-ErbB inhibitor, 5 pErk2MAPK and pAkt in Pane-I and Colo-357 cells comPD169540 (PD169) (24) (data not shown) or the selective
pared to normal HPDEC, neither of which was significantly
affected by treatment with ZD or Das (data not shown).
EGFR inhibitor, ZD I839 (ZD, Iressa) (25) (FIG. lB(ii)). In
confirmation, siRNA knockdown of c-Src abrogated
Inhibition of Stat3 Sensitizes Pancreatic Cancer Cells In Vitro
pY845EGFR levels (FIG. lB(iii), Src siRNA), while EGFR
to EGFR and Src Inhibitors.
knockdown by siRNA had minimal effect on pY 4 I 6Src level 1o
Given the preceding data on the inter-relation between
(FIG. lB(iv), EGFR siRNA). Scrambled siRNA has no effect
EGFR, Src and Stat3 activation, we investigated the biologi(FIG. lB(iii) and (iv), con siRNA). Thus, elevated
cal implications and the therapeutic potential of a combinap Y845EGFR levels in pancreatic cancer cells are sensitive to
torial approach. Dasatinib and ZD were used at I 00 nM and
Src activity.
O.I-I µM, respectively, as in literature reports (23, 24), while
Immunoblotting analysis further showed that treatment of 15 the Stat3 inhibitor, S3I-201 was used at the sub-optimum, 50
Pane-I and Colo-357 cells with ZD diminished
µM, or at the I 00 µM required to inhibit Stat3 activation (30).
pYI I73EGFR levels (FIG. lC(iii), lanes 3, 4, 8 and 9) by as
Viable cell count by trypan blue exclusion/phase-contrast
early as I h and up to 24 h, with no effect on p YI 068EGFR
microscopy showed that treatment with I µM ZD, I 00 nM
(/FIG. lC(i), lanes 3, 4, 8 and 9) orpYI086EGFR level (FIG.
Das, or 50 µM S3I-20I alone minimally affected cell viability
lC(ii), lanes 3, 4, 8 and 9), suggesting that EGFR kinase is 20 by 24 h (FIG. 3A Day I). By contrast, treatment for 48 to 96
h with or Das or S3I-20I alone progressively decreased cell
essential for the induction of p YI I 73EGFR levels, but not
viability, while treatment forthe same period with ZD showed
p YI 068EGFR or pYI 086EGFR. By contrast, Das treatment
decreased pYI068EGFR and pYI086EGFR levels (FIG.
minimal effect (FIG. 3A), except at 96 h when the number of
lC(i) and (ii), lanes 5, 6, IO and I I), with minimal effect on
viable Pane-I cells decreased (FIG. 3A(i), ZD, Day 4). CompYEGFRI I 73 (FIG. lC(iii), lanes 5, 6, 10 and I I).
25 paratively, the combined inhibition of Stat3 (by S3I-20I) and
Both EGFR and Src Promote Aberrant Stat3 Activation.
EGFR (by ZD) or Src (by Das) or the combined treatment
Both the p YI 068EGFR and p YI 086EGFR levels are bindwith AG490 (Jaks inhibitor) and ZD or Das induced greater
ing sites for Stat3 (27, 28). Given the concurrent EGFR and
losses of viability at 48-96 h (FIGS. 3A and B). The effects on
Src activation in Pane-I and Colo-357 cells, we sought to
cell viability as captured by trypan blue exclusion were condefine the regulation of aberrant Stat3 activation. By in vitro 30 firmed by the CyQuant cell proliferation/viability assay.
DNA-binding assay with EMSA analysis of nuclear extract
Unlike 24 h treatment duration that showed minimal effect on
preparations, we observe an early repression (in the first 30
viability (FIG. 3A), CyQuant assay showed that 48-h treatmin to I h of treatment) of constitutively-active Stat3 by the
ment with each inhibitor alone decreased viable cell numbers
pan-ErbB inhibitor, PD I 69540 (PD I 69), the ErbB2-selective
(quantified as fluorescent unit, FU) in a dose-dependent maninhibitor, AG879 (7), ZD, or Das (FIG. 2A(i), lanes 4, 5, 7, 35 ner (FIG. 3C, ZD, Das andS3I-201). We infer from the graphs
that treatment with I µM ZD for 48 h has minimal effect on
and 8, and (ii), lanes 2, 4, 6, and I I, and FIG. 2B, I h), or by
cell viability (FIGS. 3C(i) and (iv)), as observed by the trypan
a combined PD I 69 and Das (FIG. 2A(i ), lanes I 0 and I I, and
blue exclusion assay (FIG. 3A). However, the observed
(ii), lane 8). However, the Stat3 activity in Pane-I cells coneffects of single agents were significantly weaker compared
sistently rebounded following 24 h treatments with Das, ZD,
or PDl 69 (FIGS. 2A(i) and (ii), 24 h), even though EGFR or 40 to the concurrent treatment with a Stat3 inhibitor and an
Src activity remained inhibited (FIGS. 1B and lC, 24 h).
inhibitor of EGFR or Src. Results show that the treatment
with S3I-201 increased the sensitivity of Pane-I and ColoTwenty-four hour treatment with the AG879 moderately
inhibited Stat3 activity (FIG. 2A(ii), lane I2), which we
357 cells to ZD and Das, shifting the dose-response curves to
speculate may be due to its widespread activity as a pan-ErbB
the left (FIG. 3C, ZD+S3I-20I, and Das+S3I-20I). Concurinhibitor. By contrast, treatment with the Jak inhibitor, 45 rent treatment with S3I-20I significantly decreased the IC50
AG490 for I h had no effect on constitutive Stat3 activity, but
values as follows: I 7to 0.4 µM, and IOOto 6 nM, respectively,
surprisingly abolished Stat3 activity at 24 h treatment (FIG.
for ZD and Das against Pane-I viability (FIG. 3C(i) and (ii));
2A(ii), lanes 9 and IO). Moreover, combined treatment with
and 6.5 to 2.4 µM, and 90 to 8 nM, respectively for ZD and
Das againstColo-357 viability (FIGS. 3C(iv) and(v)). For the
AG490 and ZD, Das or PDI69 for 24 h similarly abolished
constitutively-active Stat3 (FIG. 2A(ii), lanes I4, I5, and I6). 50 impact of ZD and Das on the sensitivity to S3I-20I, CyQuant
In Colo-357, Stat3 activity was inhibited by both ZD and Das,
cell viability assay showed that Das, but not ZD increased the
with the effects more striking for Dasatinib (FIG. 2B). These
sensitivity of both cell lines to S3I-20I, decreasing its IC50
findings together reveal a pattern of constitutive Stat3 activafrom 40 to I5 µM, and from 45 to 20 µM, respectively, for
tion in pancreatic cancer cells that is mediated by both EGFR
effects on Pane-I and Colo-357 cells (FIGS. 3C(iii) and (iv)).
and Src, and a compensatory, Jak-dependent secondary Stat3 55 Thus, treatment with S3I-20I sensitized cells to ZD and Das,
activity. A similar pattern of Stat3 activation has been
while treatment with Das, but not ZD similarly sensitized
cells to S3I-201.
observed in head and neck squamous carcinoma, mesothelioma, squamous cell skin carcinoma, and non-small cell lung
Given the clinical implications of these findings, we
extended these studies to examine the effect ofEGFR Src and
cancer cell lines following the inhibition of Src (29). In further support, the siRNAknockdown ofEGFR (EGFR siRNA) 60 Stat3 pathway on the response to Gemcitabine, the anti-metabolite agent used in the treatment of pancreatic cancer.
or Src (Src siRNA) led to pStat3 suppression, as assayed by
immunoblotting analysis (FIG. 2C). Scrambled siRNA (con)
CyQuant cell proliferation/viability studies showed that inhibition ofEGFR, Src or Stat3 sensitized Pane-I and Colo-357
has no effect. Immunoblotting analysis also shows that EGF
stimulation
induces
pY705Stat3,
pYI086EGFR,
cells to Gemcitabine (FIG. 3D). More importantly, the compYII73EGFR, pY845EGFR and pY4I6c-Src (Supplemen- 65 bined inhibition of Stat3 and EGFR or Src induced a higher
sensitization of cells to Gemcitabine than that induced by the
ta! FIG. Sl(i)-(iii), lane 4) over and above constitutive levels
in Pane- I cells, in a manner that is similar to the induction of
inhibition of any one alone (FIG. 3D).
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As known to the skilled, Gemcitabine is a nucleoside analog of cytidine which interferes with DNA replication, arresting tumor growth and resulting in apoptosis of the cell. Gemcitabine is also known to bind to the active site of the enzyme
ribonucleotide reductase (RNR) to irreversibly inactive the
enzyme, thus interfering with the cell's ability to produce
deoxyribonucleotides necessary for DNA replication and
repair. This also leads to apoptosis. As noted above, the combined inhibition of Stat3 and EGFR or Src induces a higher
sensitization of cells to Gemcitabine, creating another possibility for combination therapy of tumors.
To further explore the sensitization potential of inhibition
of aberrant Stat3, we performed colony survival assay (19).
Results show that inhibition of Src (by Das) or Stat3 (by
S3I-201 (S3I)), but not EGFR inhibition (by ZD) resulted in
reduced colony numbers (FIG. 4A). More importantly, the
concurrent inhibition of Stat3 and EGFR or Src resulted in
much lower colony numbers (FIG. 4A), consistent with the
much greater loss of viable cells due to the combined inhibition of Stat3 and EGFR or Src (FIG. 3). To extend these
studies, we performed Annexin V binding/Flow Cytometric
analysis for apoptosis. Higher percentages of Pane- I and
Colo-357 cells undergoing apoptosis were observed for concurrent inhibition of Stat3 and EGFR or Src than for the
inhibition any one signaling molecule alone (FIG. 4B(ii) and
(iii)). Similar results were obtained for the concurrent treatments withAG490 and ZD or Das (FIG. 4B(ii) and (iii)). By
contrast, similar treatments of normal HPDECs showed no
significant apoptosis (FIG. 4B(i)) with the combination treatments. Thus, we establish that pancreatic cancer cells have
higher sensitivity to concurrent inhibition ofStat3 and EGFR
or Src than to the inhibition of a single entity.
EGFR, Src and Stat3 Together Promote Pancreatic Cancer
Cell Migration and Invasion.
Aberrantly-active Src and Stat3 have both been implicated
in tumor cell motility, migration, invasion and metastasis (4,
23). in vitro matrigel assay confirmed that inhibition ofSrc or
Stat3 alone suppresses migration and invasion (FIG. SA).
However, concurrent inhibition of Stat3 and EGFR or Src for
24-h has a stronger effect on Colo-357 migration and Pane-I
invasion, except for Src inhibition, which showed a similar
effect on Pane-I migration (FIG. SA). At the 24-h treatment
when these studies were done, there is no significant effect on
cell viability (FIG. 3). These findings are further evidence that
pancreatic cancer lines are more sensitive to concurrent inhibition of Stat3 and Src or EGFR.
EGFR, Src and Stat3 Module Regulates c-Myc Over-Expression in Pancreatic Cancer Cells.
For insight into the underlying molecular mechanisms by
which the EGFR, Src and Stat3 pathway may support the
cancer phenotype, we studied the regulation of key cancerrelevant genes. We show that c-Myc is over-expressed in
pancreatic cancer lines compared to normal HPDEC (FIG.
SB). Furthermore, the concurrent inhibition of Stat3 and
EGFR or Src consistently repressed c-Myc expression. These
findings suggest a functional synergy between EGFR, Src and
Stat3 in inducing c-Myc expression in the context of pancreatic cancer phenotype and that the stronger repression of
c-Myc expression contributes to the antitumor cell effects of
and the increased sensitivity of pancreatic cancer lines to
concurrent Stat3 and EGFR or Src inhibition.
Inhibition of Tumor Growth by Combination Treatment
Concurrent inhibition of Stat3 and EGFR or Src induces
human pancreatic tumor growth inhibition in xenografts.
Subcutaneous xenografts of Colo-357, a metastatic pancreatic adenocarcinoma line were used to study the therapeutic
implication of the Stat3, EGFR and Src inter-relationships

and to evaluate the in vivo antitumor effects of concurrent
inhibition of Stat3 and EGFR or Src. Data showed that in
general, xenografts ofColo-357 cells showed low responsiveness to treatment with inhibitor ofEGFR, Src or Stat3 alone,
although, as the therapy progressed, those tumors treated with
only one inhibitor alone appeared to show reduced growth,
which was statistically not significant from the control, nontreated tumors (FIG. 6). By contrast, tumors from mice
treated with combined S3I-201 and Das or S3I-201 and ZD
consistently showed reduced growth and smaller tumor sizes
throughout the entire study (FIG. 6). Thus, the residual tumor
volumes (sizes) for tumors in mice treated with combination
inhibitors were significantly different (p<0.05) from tumor
volumes for tumors in control mice at days 20 and upwards
post treatment. These in vivo antitumor effects of combination treatment with inhibitors ofS3I-201 and Das or S3I-201
and ZD are consistent with the in vitro antitumor cell data and
together indicate that aberrant Stat3 cooperates with hyperactive EGFR or Src to sustain human pancreatic cancer.
Discussion
Within the context of aberrations in the EGFR, Src and
Stat3 pathway in pancreatic cancer, present study reveals a
strong role for Src in supporting aberrant EGFR activation by
not only inducing the phosphorylation ofY845EGFR motif
(31 ), but also promoting the induction of pYI 068EGFR and
pYI086EGFR motifs. These Src-promoted events will
greatly influence the status of EGFR in pancreatic cancer
cells. A role for EGFR in aberrant Stat3 activation in cancer
cells has previously been reported in other tumor cells,
including head and neck squamous cell carcinoma and breast
cancer (26, 32). Present study extends those findings to pancreatic cancer and show that EGFR is key in facilitating
aberrant Stat3 activation. Moreover, the pYI 068EGFR and
pYI086EGFR induction by Src is likely to have significant
impact on the activation of Stat3, given that these two motifs
are essential sites for the binding of Stat3 to EGFR in order to
promote its phosphorylation and activation (27, 28). Furthermore, Src may not only facilitate Stat3 activation via the
induction of those two Tyr motifs of EGFR, but it can also
directly phosphorylate Stat3, as has been previously reported
in other systems (18). It is therefore consistent that both
hyperactive EGFR and Src promote baseline constitutive
Stat3 activation in pancreatic cancer, as revealed by our study.
The present study is also in agreement with an earlier report
of ErbB-2-dependent constitutive Stat3 activation in MiaPaca-2 and UK Pan-I cells (7) and another study that showed
that the full induction of Stat3 activation by ErbB2 required
both Src and Jaks (33). Our findings indicate that Jaks contribute to the maintenance of constitutive activation in revealing a Jak-dependent compensatory mechanism of Stat3 activation upon inhibition of EGFR and Src. Given that Jaks
inhibition did not abolish aberrant Stat3 at the earliest time
point, we deduce that this family of cytoplasmic tyrosine
kinases may not be the predominant mediators of the baseline
aberrant Stat3. Thus, in pancreatic cancer cells, a two-phase
model of activation of Stat3 signaling emerges composed of
an EGFR- and Src-dependent baseline, constitutive Stat3
induction, and an induced Stat3 activation that is dependent
on Jaks. The observed secondary induction ofStat3 activation
via Jaks has similarly been reported in head and neck squamous cell carcinoma line (29) and could be due to growthstimulatory factors released from tumor cells (34), which in
turn would induce the activation of Jaks and thereby promote
Stat3 activation.
EGFR, Src and Stat3 has each independently been established to have critical roles in malignant transformation (6,
14, 23, 26, 35), while their collective roles in promoting
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tumorigenesis have not been explored. While the inhibition of
the activity of each of the three proteins induced antitumor
cell response to some degree, data presented here strongly
indicate that the multiple targeting of Stat3 and EGFR or Src
together has a higher potential to inhibit growth, viability,
survival, malignant transformation, and migration and invasion in vitro.
Significantly, hyperactivation of the EGFR signaling has
been deemed a prognostic indicator of low survival among
pancreatic cancer patients (36-38). Also, there is evidence to
indicate that the concurrence with aberrant Src signaling
potentiates the effects of aberrant EGFR and induces biological synergy (3, 21, 39). Given the potential collective roles of
Stat3, EGFR and Src in promoting and supporting pancreatic
cancer, the inhibition of any single entity alone is unlikely to
be insufficient to impact the disease. Present data that simultaneous inhibition of Stat3 and EGFR or Src induced greater
antitumor cell effects and a higher sensitization to Gemcitabine provides a strong support for the opinion that Stat3 may
cooperate with EGFR and Src to support the malignant phenotype. Indeed, the inhibition of Stat3 seemed to sensitize
pancreatic cancer cells to the antitumor cell effects of ZD and
Das. Multiple targeting of Stat3 and EGFR or Src therefore
has the potential to induce a greater anti tumor efficacy. This is
supported by our present data that concurrent treatment with
theStat3 inhibitor, S3I-201 and ZD or Das induced greater
regression of xenografts of Colo-357 than treatment with
either inhibitor alone. Such a multiple-targeted therapy has
received a strong interest in recent times, particularly given
the dismal results in certain cases of molecular targeted
monotherapy, such as anti-EGFR monotherapy (40, 41).
Thus, a combined Gemcitabine and Erlotinib (EGFR TK
inhibitor) therapy has recently been approved for patients
with locally advanced/metastatic pancreatic cancer (42, 43),
although we note by our data that the inhibition of Stat3 and
EGFR or Src together induces a higher Gemcitabine sensitivity than inhibition ofEGFR alone. The enhanced anti tumor
effects due combined Stat3 and EGFR or Src inhibitors may
in part be due stronger repression of the expression of c-Myc
oncogene. Altogether, present study provides support for a
multiple-modality therapeutic approach and lays the foundation for concurrent targeting of aberrant Stat3 and EGFR or
Src as a more effective approach for achieving an enhanced
antitumor therapeutic efficacy in pancreatic cancer.
Accordingly, in the drawings and specification there have
been disclosed typical preferred embodiments of the invention and although specific terms may have been employed, the
terms are used in a descriptive sense only and not for purposes
of limitation. The invention has been described in considerable detail with specific reference to these illustrated embodiments. It will be apparent, however, that various modifications and changes can be made within the spirit and scope of
the invention as described in the foregoing specification and
as defined in the appended claims.
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